On September 5, 2019 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, reported the Company’s CEO Dr. Pnina Fishman will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City (Press release, Can-Fite BioPharma, SEP 5, 2019, https://ir.canfite.com/news/detail/864/can-fite-to-present-at-h-c-wainwright-21st-annual-global-investment-conference-on-september-10-2019 [SID1234539298]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Fishman will present on Tuesday, September 10th at 3:00 p.m. in the Kennedy I room, 4th floor. Company executives will also conduct one-on-one meetings with institutional investors.